In this episode, Dr. Adam Luginbuhl, Dr. Dylan Roden, and Dr. Ravindra Uppaluri discuss the evolving role of neoadjuvant therapy in head and neck cancer, with particular focus on the recent approval of Keynote-689. The conversation covers patient selection, surgical timing, and coordination across multidisciplinary teams to optimize outcomes. The experts also share insights on balancing oncologic control with functional preservation and how future data may continue to shape neoadjuvant treatment strategies.
Contributors:
Dr. Adam Luginbuhl is an Associate Professor of Otolaryngology Head and Neck Surgery at Thomas Jefferson University.
Dr. Dylan Roden is a head and neck cancer surgeon and Chair of Robotic Surgery at Rutgers New Jersey Medical School.
Dr. Ravindra Uppaluri is the Director of Head and Neck Surgical Oncology at the Brigham and Women’s Hospital in Boston, Massachusetts.
